Accumulation of Phosphorylated α‐Synuclein in Aging Human Brain

α-Synuclein in Lewy bodies (LBs) is phosphorylated at Ser129. We raised monoclonal and polyclonal antibodies to this phosphorylation site (psyn) and examined 157 serial autopsy brains from a geriatric hospital. Anti-psyn immunoreactivity was observed in 40 of these cases (25.5%). Immunohistochemistry revealed 4 novel types of pathology: diffuse neuronal cytoplasmic staining (pre-LB); neuropil thread-like structures (Lewy threads); dot-like structures similar to argyrophilic grains (Lewy dots); and axons in the white matter (Lewy axons). This novel pathology was abundantly present around LBs and also involved the limbic subcortical white matter, the cerebral cortical molecular layer, and the spongiform changes of the medial temporal lobe associated with cases of dementia with LBs (DLB). The phosphorylated α-synuclein was limited to the temporal lobe in cases of Parkinson disease, spread from the temporal lobe to the frontal lobe in cases of DLB transitional form and further spread to the parietal and occipital lobes in DLB neocortical form. Our findings suggest that LB-related pathology initially involves the neuronal perikarya, dendrites, and axons, causes impairment of axonal transport and synaptic transmission, and later leads to the formation of LBs, a hallmark of functional disturbance long before neuronal cell death.

[1]  Michel Goedert,et al.  Identification of two distinct synucleins from human brain , 1994, FEBS letters.

[2]  T. Kato,et al.  Spinal cord lesions in progressive supranuclear palsy: some new observations , 1986, Acta Neuropathologica.

[3]  G. Asano,et al.  α-Synuclein-positive structures in cases with sporadic Alzheimer’s disease: morphology and its relationship to tau aggregation , 2001, Brain Research.

[4]  M. L. Schmidt,et al.  α-Synuclein in Lewy bodies , 1997, Nature.

[5]  K. Ishii,et al.  Regional cerebral blood flow difference between dementia with Lewy bodies and AD , 1999, Neurology.

[6]  K. Davis,et al.  Neocortical cholinergic activities differentiate Lewy body dementia from classical Alzheimer's disease. , 1994, Neuroreport.

[7]  J. Saint-Cyr,et al.  Parkinson's disease and dementia , 1989, Neurology.

[8]  S. Murayama,et al.  Severe Involvement of Ambient Gyrus in Dementia with Grains , 2002, Journal of neuropathology and experimental neurology.

[9]  J. Trojanowski,et al.  Phosphorylated α-Synuclein Is Ubiquitinated in α-Synucleinopathy Lesions* , 2002, The Journal of Biological Chemistry.

[10]  J. Trojanowski,et al.  Novel antibodies to synuclein show abundant striatal pathology in Lewy body diseases , 2002, Annals of neurology.

[11]  Hiroaki Kazui,et al.  Regional cerebral glucose metabolism in dementia with Lewy bodies and Alzheimer's disease: a comparative study using positron emission tomography , 1997, Neuroscience Letters.

[12]  K. Iwanaga,et al.  Lewy body–type degeneration in cardiac plexus in Parkinson’s and incidental Lewy body diseases , 1999, Neurology.

[13]  I. Kanazawa,et al.  Widespread expression of α-synuclein and τ immunoreactivity in Hallervorden–Spatz syndrome with protracted clinical course , 2000, Journal of the Neurological Sciences.

[14]  C. P. Hughes,et al.  A New Clinical Scale for the Staging of Dementia , 1982, British Journal of Psychiatry.

[15]  A. Lees PARKINSON'S DISEASE AND DEMENTIA , 1985, The Lancet.

[16]  I. McKeith,et al.  Dementia with Lewy bodies , 2004, The Lancet Neurology.

[17]  H. Braak,et al.  Argyrophilic grains: characteristic pathology of cerebral cortex in cases of adult onset dementia without Alzheimer changes , 1987, Neuroscience Letters.

[18]  E. Masliah,et al.  α-Synuclein is phosphorylated in synucleinopathy lesions , 2002, Nature Cell Biology.

[19]  J Q Trojanowski,et al.  Lewy bodies contain altered alpha-synuclein in brains of many familial Alzheimer's disease patients with mutations in presenilin and amyloid precursor protein genes. , 1998, The American journal of pathology.

[20]  I G McKeith,et al.  Report of the second dementia with Lewy body international workshop , 1999, Neurology.

[21]  J. Trojanowski,et al.  Tau and α-Synuclein Pathology in Amygdala of Parkinsonism-Dementia Complex Patients of Guam , 2002 .

[22]  H. Braak,et al.  Neuropathological stageing of Alzheimer-related changes , 2004, Acta Neuropathologica.

[23]  E. Mori [Dementia with Lewy bodies]. , 2000, Nihon Ronen Igakkai zasshi. Japanese journal of geriatrics.

[24]  J Q Trojanowski,et al.  Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. , 1998, The American journal of pathology.

[25]  I. Kanazawa,et al.  Widespread expression of alpha-synuclein and tau immunoreactivity in Hallervorden-Spatz syndrome with protracted clinical course. , 2000, Journal of the neurological sciences.

[26]  Udo Rüb,et al.  Where Does Parkinson Disease Pathology Begin in the Brain? , 2002, Journal of neuropathology and experimental neurology.

[27]  I G McKeith,et al.  Striatal dopaminergic markers in dementia with Lewy bodies, Alzheimer's and Parkinson's diseases: rostrocaudal distribution. , 1999, Brain : a journal of neurology.